Case Overview
This brief summarizes Syngenta AG’s publicly disclosed transfer pricing disputes in Brazil, as described in Syngenta’s financial reports. The disclosures indicate multiple Brazilian transfer pricing assessments covering fiscal years 2003, 2011, 2013–2015, and 2016, with proceedings at different stages in administrative and judicial channels.
No publicly available, reasoned Brazilian decision text naming Syngenta was located in the sources reviewed; the facts and legal arguments are known primarily through financial statement disclosure.
Key Facts
- Syngenta is headquartered in Switzerland (Syngenta AG) but operates globally, including in Brazil, with intercompany flows that may be reviewed under transfer pricing rules (Syngenta Financial Report 2021).
- Syngenta disclosed Brazilian transfer pricing disputes with a mixed procedural posture:
- FY2003 and FY2011: adverse outcomes at the administrative level; Syngenta appealed to the civil/judicial level (Syngenta Financial Report 2021).
- FY2013–FY2015: assessments appealed at the administrative level and cancelled at first instance (Syngenta Financial Report 2021; similar disclosure language also appears in later reports).
- FY2016: Syngenta disclosed that it was assessed in 2021 and that it filed an administrative appeal seeking cancellation (Syngenta Financial Report 2021).
- Syngenta disclosed no recognized liability for these disputes and reported estimated aggregate contingent liabilities of $213 million as of Dec. 31, 2021 (2020: $130 million) (Syngenta Financial Report 2021).
- Brazil’s historical transfer pricing framework (per OECD’s 2022 profile) differed from the OECD standard: no direct statutory reference to the arm’s length principle, reliance on formulaic methods with fixed margins, and no TNMM/profit split in the domestic framework (OECD Brazil TP Country Profile, Feb. 2022).
The Dispute
Syngenta’s disclosures do not identify the specific intercompany transactions, tested parties, methods applied by auditors, or any adjustment computations. The reports describe the disputes at a high level as transfer pricing assessments and related appeals.
Given Brazil’s rules as summarized by the OECD (Feb. 2022), Brazilian transfer pricing controversies commonly turn on:
- whether a transaction is within scope and correctly classified (e.g., imports/exports of goods, services/rights, intra-group loans);
- whether the taxpayer correctly applied domestic statutory methods and parameters (including fixed margins and mandated approaches for certain transactions, such as commodities and intra-group interest).
Accordingly, while Syngenta is an intangible-heavy multinational, the public materials do not support attributing this dispute to a particular IP migration or DEMPE controversy. Any such characterization would be speculative on the current record.
Holding
No published merits “holding” could be verified from an identified Brazilian court/tribunal decision in the sources reviewed.
The verifiable outcome is procedural and mixed (Syngenta Financial Report 2021):
- Syngenta reported first-instance administrative wins (cancellation) for FY2013–FY2015.
- Syngenta reported adverse administrative rulings for FY2003 and FY2011 and ongoing judicial appeals.
- Syngenta reported a new assessment for FY2016 (issued in 2021) and an administrative appeal seeking cancellation.
Takeaways for Practitioners
- Do not assume an OECD-style arm’s length analysis in legacy Brazilian disputes: Brazil’s pre-reform framework is described by the OECD as non-arm’s-length in statute and formulaic in design (OECD Brazil TP Country Profile, Feb. 2022).
- When briefing disputes disclosed in financial statements, clearly separate:
- what is evidenced (years under dispute, procedural stage, disclosed exposure), from
- what is unknown (transaction facts, method application, adjustment mechanics).
- Multi-year controversies can produce mixed outcomes across years and forums (administrative vs judicial), so risk assessments should track each year’s procedural path separately.
- Where cross-border double taxation is plausible, consider whether treaty MAP could be relevant (Brazil reports MAP availability in the OECD profile), but confirm treaty coverage and practical access in the specific period.
Related Content
For practical guidance, see Documentation for Intangibles and the glossary entry on the Arm's Length Principle. While the disclosed Brazilian disputes are not described as “intangibles cases,” robust documentation remains important where intercompany services, rights, or financing are involved.
Frequently Asked Questions
Q1. Is this a Swiss Federal Tax Administration (SFTA) case from 2019?
A. No. The sources reviewed (Syngenta financial reports) describe the disclosed transfer pricing assessments and appeals as Brazilian disputes involving multiple fiscal years, not a published Swiss decision.
Q2. What years are involved in Syngenta’s disclosed Brazilian transfer pricing disputes?
A. Syngenta disclosed disputes covering FY2003 and FY2011 (administratively adverse; appealed judicially), FY2013–FY2015 (cancelled at first administrative instance), and FY2016 (assessed in 2021; appealed administratively) (Syngenta Financial Report 2021).
Q3. How much tax is at stake?
A. Syngenta disclosed estimated aggregate contingent liabilities of $213 million as of Dec. 31, 2021 related to these disputes and stated it recognized no liability (Syngenta Financial Report 2021).
Q4. Why does the Brazilian TP framework matter to interpreting these disputes?
A. The OECD’s Brazil profile (Feb. 2022) states that Brazilian TP legislation does not directly reference the arm’s length principle and historically relies on formulaic methods (and does not provide for TNMM/profit split in the domestic framework). That affects the likely issues in audit and litigation.
Q5. What is the main limitation of this “case” brief?
A. There is no publicly available merits decision in the cited sources, and the disclosures do not provide transaction-level facts, methods, or computations—so the brief is limited to the existence of the disputes, their procedural posture, and disclosed financial exposure.